Avalo Therapeutics (AVTX) Goodwill (2017 - 2026)

Avalo Therapeutics' Goodwill history runs 10 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• Quarterly Goodwill changed 0.0% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (changed 0.0% YoY) and the FY2025 annual result came in at $10.5 million, changed 0.02% from the prior year.
• Goodwill was $10.5 million for Q1 2026 at Avalo Therapeutics, roughly flat from $10.5 million in the prior quarter.
• Across five years, Goodwill topped out at $14.4 million in Q1 2022 and bottomed at $10.5 million in Q4 2024.
• A 5-year average of $12.1 million and a median of $10.5 million in 2023 frame the typical range for Goodwill.
• Annual changes were most pronounced in 2023 — Goodwill decreased 27.11% — and 2025, when it gained 0.02%.
• Avalo Therapeutics' Goodwill stood at $14.4 million in 2022, then dropped by 27.11% to $10.5 million in 2023, then declined by 0.02% to $10.5 million in 2024, then increased by 0.02% to $10.5 million in 2025, then changed by 0.0% to $10.5 million in 2026.
• Business Quant data shows AVTX's Goodwill at $10.5 million in Q1 2026, $10.5 million in Q4 2025, and $10.5 million in Q3 2025.